AstraZeneca issued a statement on Monday defending its COVID-19 vaccine after some countries raised concerns about blood clots in vaccine containers and called for a temporary suspension.
The company said there was “no evidence of an increased risk” of blood clots after receiving its injection.
Ireland announced on Sunday that it would temporarily suspend the distribution of the vaccine “very cautiously,” Reuters reported. The move was announced after reports of blood clotting at some of the recipients in Norway.
AstraZeneca, a company in Cambridge, UK, said more than 17 million people were vaccinated with injections in the European Union and the UK, and there was “no evidence of an increased risk of pulmonary embolism, deep vein thrombosis or thrombocytopenia. , in any defined age range, gender, lot, or any country in particular. “
The statement pointed to cases of pulmonary embolism and said that the number of such cases after receiving the injection is “much less than would be expected to occur naturally in a general population of this size and is similar in other licensed COVID-19 vaccines.”
The Netherlands accompanied Ireland at the end of Sunday and announced that it was suspending vaccination with the AstraZeneca vaccine as a precaution for two weeks. The health ministry said the move came after six new reports in Denmark and Norway of blood clotting and reduced platelet levels in people under 50.
DENMARK SUSPENDS USE OF ASTRAZENECA COVID-19 VACCINE FOLLOWING BLOOD COLLEAGUE REPORTS
The Dutch drug authority also emphasized that no link has been proven between the cases and the vaccine.
CLICK HERE TO GET THE FOX NEWS APPLICATION
The World Health Organization and the European Union’s drug regulator said earlier that there was no link between the injection and an increased risk of developing a clot.
The Associated Press contributed to this report